Our Blog - ELIAS Animal Health: Insights on Cancer Immunotherapy

ELIAS Animal Health Appoints Chief Revenue Officer; Launches Fundraising Round to Support Commercialization and Development of Innovative Canine Cancer Therapies

Experienced executive will lead launch of the first USDA-approved immunotherapy for the treatment of bone cancer in dogs OLATHE, Kan., [...]

April 10th, 2024|

ELIAS Animal Health CEO, Tammie Wahaus, returns to the Dog Cancer Answers podcast to talk about ECI® as an alternative [...]

April 1st, 2024|

First-in-class adoptive cell therapy for treatment of osteosarcoma, a deadly form of bone cancer in dogs OLATHE, Kan., Jan. 17, [...]

January 17th, 2024|

After successfully concluding a clinical trial for canine osteosarcoma, ELIAS Animal Health is focused on continuing to push forward in [...]

November 2nd, 2023|

Pets bring us immense joy and companionship, making them cherished members of our families. However, just like humans, they too [...]

October 31st, 2023|

ELIAS Animal Health previously announced it has in-licensed an oncolytic vaccinia virus treatment for pet animals from Genelux Corporation. The [...]

October 13th, 2023|

Our mission at ELIAS Animal Health is to improve cancer treatment outcomes in veterinary patients through the advancement of innovative [...]

April 26th, 2023|